Shanghai Fudan Forward S&T Co

Shanghai Fudan Forward S&T Co Net Margin

The Net Profit Margin of Shanghai Fudan Forward S&T Co (600624.SS) as of Oct 29, 2026 is -30.86 %. In the previous year, Net Profit Margin was -20.64 % — a change of 49.50% (lower).

Net Margin

-30.86 %

YoY

49.50%

Last updated:

Net Profit Margin of Shanghai Fudan Forward S&T Co is 2025 -30.86 % . Net Profit Margin of Shanghai Fudan Forward S&T Co was 2024 -20.64 % . It decreases by 49.50% lower compared to the previous year.

Shanghai Fudan Forward S&T Co's net margin stands at -30.9%, down from -10.1% several years earlier.

The Shanghai Fudan Forward S&T Co Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
4.24 CNY
Jan 1, 2019
3.97 CNY
Jan 1, 2020
-6.34 CNY
Jan 1, 2021
-10.12 CNY
Jan 1, 2022
-0.79 CNY
Jan 1, 2023
-3.22 CNY
Jan 1, 2024
-20.64 CNY
Jan 1, 2025
-30.86 CNY
The Shanghai Fudan Forward S&T Co Net Margin history
YEARNet MarginYoY
-30.86 %+49.50%
-20.64 %+541.87%
-3.22 %+309.25%
-0.79 %-92.24%
-10.12 %+59.58%
-6.34 %-259.99%
3.97 %-6.56%
4.24 %-26.49%
5.77 %+1.56%
5.68 %-21.93%
7.28 %+81.09%
4.02 %+11,248.94%
0.04 %+9.46%
0.03 %-0.85%
0.03 %-4.40%
0.03 %+36.29%
0.03 %-36.93%
0.04 %-2.08%
0.04 %-2.94%
0.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Fudan Forward S&T Co Stock analysis

What does Shanghai Fudan Forward S&T Co do? Shanghai Fudan Forward S&T Co., Ltd. generates revenue through the research, development, production, and sale of pharmaceutical products, including digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, and immune function medications. The company also provides financial insurance software products. Its domestic and overseas markets serve as key sales channels for these pharmaceuticals and software solutions. The firm's product portfolio targets healthcare providers, hospitals, and pharmacies within the pharmaceutical sector. The company's pharmaceutical segment focuses on specialized drug categories such as digestive system and nervous system treatments, alongside antineoplastic and circulatory drugs. Financial insurance software products complement its core pharmaceutical business, offering additional revenue streams. Domestic markets account for a significant portion of sales, while overseas markets expand its global reach. Shanghai Fudan Forward S&T Co., Ltd. leverages its 1,426 full-time employees to support both pharmaceutical and software operations. The firm's product offerings cater to healthcare institutions requiring specialized medications and digital solutions for insurance management. This dual focus allows the company to serve multiple segments within the healthcare and financial technology industries. Shanghai Fudan Forward S&T Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Fudan Forward S&T Co stock

Net Profit Margin of Shanghai Fudan Forward S&T Co is -30.86 % in 2025.

Net Profit Margin of Shanghai Fudan Forward S&T Co changed from -20.64 % to -30.86 %, representing a 49.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Shanghai Fudan Forward S&T Co since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Shanghai Fudan Forward S&T Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Shanghai Fudan Forward S&T Co

All Key Metrics — Shanghai Fudan Forward S&T Co